A study on the effectiveness of twice daily split dosage regimen of deferasirox by analysing serum ferritin levels in beta thalassemia patients who are already on single daily deferasirox regimen.
Not Applicable
- Conditions
- Health Condition 1: null- Beta thalassemia patients who are already on deferasirox single daily regimen.
- Registration Number
- CTRI/2016/09/007299
- Lead Sponsor
- issar moopan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 25
Inclusion Criteria
All patients diagnosed with beta thalassemia and on regular blood transfusion receiving once daily deferasirox.
2)Serum ferritin > 1500 mcg/L.
3)All thalassemia patients who are not on regular IV chelation therapy (receiving IV chelation during every transfusion)
Exclusion Criteria
1)All thalasemia patients who are on oral deferiprone therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To asess the response to intervetion by serial serum ferritin level assesment at 6 monthsTimepoint: To asess the response to intervetion by serial serum ferritin level assesment at 6 months
- Secondary Outcome Measures
Name Time Method To asess the response to intervetion by serial serum ferritin level assesment at 0,3 monthsTimepoint: To asess the response to intervetion by serial serum ferritin level assesment at 0,3 months